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doi:10.1016/j.asjsur.2012.04.003Summary Objective: Massive hemothorax in patients on extracorporeal membrane oxygena-
tion (ECMO) is potentially life threatening and remains a medical challenge. In this study, we
present the clinical results of using aggressive management to treat a consecutive series of
patients on ECMO whose conditions were complicated by massive hemothorax.
Methods: Between November 2003 and February 2010, 14 adult patients on ECMO developed
massive hemothorax that was unrelated to the cannulation problems of the ECMO circuit at
National Taiwan University Hospital, Taipei, Taiwan. Information was obtained regarding
patient demographics, disease course, and treatment. Aggressive treatment of hemothorax
included blood component therapy, chest tube drainage, pleural epinephrine irrigation, and
surgical intervention. The criteria for surgical intervention, video-assisted thoracoscopic
surgery (VATS), or open-window thoracostomy included one-third or more of the thoracic
cavity that had accumulated blood clots resulting in a compromised cardiopulmonary status,
continuous blood loss > 300 mL/hour for 4 hours or more, or continued bleeding for 24 hours
after persistent blood transfusion.
Results: All hemothoraces were unilateral. With coagulopathic correction, control of bleeding
was obtained in two patients after decompression of the pleural cavity, four patients after
pleural epinephrine irrigation, and eight of 14 patients required surgical intervention for blood
clot evacuation. There were no specific findings except blood clot accumulation in each of the
patients who underwent thoracotomy or VATS. Three of the eight patients required multiple
operations to treat persistent bleeding. The in-hospital mortality rate was 36% (5 of 14
patients); one patient died of intractable bleeding and four deaths were related to multipleThoracic Surgery, Department of Surgery, National Taiwan University Hospital, 7, Chung-Shan South
(Y.-C. Lee).
n Surgical Association. Published by Elsevier Taiwan LLC. All rights reserved.
Massive hemothorax and ECMO 17organ failure. Blood transfusion (Mann-Whitney U test; pZ 0.039) and comorbidities such as
bacteremia, septic shock, diabetic mellitus, and immunocompromised status (Fisher exact
test; pZ 0.031) were found to be significant and independent predictors of mortality.
However, other factors such as age, complicated pneumothorax, and ECMO circuit duration
were not statistically correlated with mortality.
Conclusion: ECMO-related massive hemothorax usually occurred unilaterally and presented as
a life-threatening condition. With intensive treatment, nearly two-thirds of the patients were
saved. The most significant risk factor for mortality was the presence of a comorbidity such as
sepsis, diabetic mellitus, or immunocompromised status.
Copyright ª 2012, Asian Surgical Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Extracorporeal membrane oxygenation (ECMO) is interna-
tionally used as a viable, life-saving cardiopulmonary
intervention that to treat a variety of critical ill
patients.1e4 However, the complication of massive hemo-
thorax in patients undergoing ECMO remains a medical
challenge and is potentially life threatening because of the
underlying problems of bleeding tendency,5 associated
multiple organ failure, and the difficulty of performing the
surgical techniques required for its treatment.6 Although
hemothorax has been recognized as a clinical entity for
centuries, the surgical strategies for its management,
especially when complicated by ECMO, are rarely described
in detail in the medical literature. On review of the liter-
ature, only adjustments to the heparin dosage6 and the
drainage of pleural hemorrhage7 are mentioned. This study
summarizes the multimodal approach and related prog-
nostic factors for treating patients with ECMO-related
massive hemothorax.
2. Patients and methods
2.1. Study design
This retrospective cohort study, which was approved by the
institutional research board of our institution, included all
of the consecutive adult ECMO patients who were treated
at the National Taiwan University Hospital between
November 2003 and February 2010. In general, the indica-
tion for ECMO was severe cardiopulmonary disorder when
all other management options failed.
2.2. Case selection and hemothorax management
Patients with massive hemothorax that met the criteria of
rapid accumulation of pleural hematoma and the shifting of
the mediastinal structures that were recognizable on
bedside imaging were included in this study. In total, 14
consecutive adult ECMO patients with massive hemothorax
(unrelated to ECMO cannulation or cardiopulmonary resus-
citation) were enrolled into this study. The medical records
included each patient’s sex, event that resulted in pleural
hemorrhage, and specific interventions that were adminis-
tered with respect to variations in chest tube output andblood transfusion requirements. Daily anteroposterior chest
radiographs were obtained during ECMO support for all 14
patients. Sonograms were used to verify any radiographi-
cally suspected pleural fluid and on follow-up examinations
of any hemorrhage.
The patients with ECMO-related massive hemothorax
were initially managed by simultaneous replacement of
blood volume and drainage of hemothorax by chest tube
thoracostomy. The volume of blood initially drained from
the chest tube and the rate of continuous blood loss were
used to decide the amount of replacement intravenous
fluid. Low-dose heparin infusion as part of the ECMO circuit
(100 U/kg heparin) was discontinued and all subjects were
prescribed 500 mg q8h tranexamic acid via intravascular
injection to control bleeding. We also used pleural
epinephrine irrigation through the chest tube at a rate of
5 mg epinephrine/1000 mL normal saline. Two hundred mL
was infused each time and retained for 15 minutes and then
released, and the procedure was repeated no more than
five times. In addition, the surgical indications included
continuous blood loss > 300 mL/hour over a period of 4
hours, persistent blood transfusion requirements,
continued bleeding for 24 hours, or, more often, the
accumulation of blood clots in one-third or more of the
chest cavity that resulted in compromised cardiopulmonary
status. The surgical strategies included video-assisted
thoracoscopic surgery (VATS) for detecting the source of
the bleeding and evacuating the blood clots. Hemostasis
was achieved by clip ligation and electrocautery. VATS was
converted to open-window thoracostomy with dressing and
packing if control of the refractory bleeding failed. The wet
dressings were frequently changed for postoperative
hemostasis, and continuous pleural epinephrine irrigation
was administered through a chest tube (Fig. 1).
2.3. ECMO circuit management
At our institution, the ECMO circuit consists of a centrifugal
pump, a hollow-fiber microporous membrane oxygenator
with an integrated heater, and percutaneous thin-wall
cannula (CB2505; Medtronic Inc., Anaheim, CA, USA), all of
which are coated with a heparin-bound Carmeda Bioactive
Surface. A silicone membrane oxygenator (I-4500-2A; Med-
tronic BioMedicus, Inc, Minneapolis, Minn, U.S.A.) is used in
the ECMO circuit when prolonged ECMO support is required
because the microporous membrane oxygenator cannot last
Figure 1 Schematic illustration showing soaked dressings in
an open-window thoracostomy and epinephrine irrigation
through tubes between the dressings and the lung. A) Front
view showing the dressings in an open-window thoracostomy
with intermittent epinephrine irrigation and the retention of
hemostasis. B) Lateral view showing epinephrine irrigation
through chest tubes that were placed between the lung
parenchyma and the dressings.
18 P.-M. Huang et al.for long periods of time. Heparin (100 U/kg) was adminis-
tered to the patient before cannulation, and then continuous
heparin infusion was used to keep the whole blood activated
clotting time (ACT) in the range of 160e220 seconds (normal:
 120 seconds) in order to prevent ECMO-related hemolysis
or thrombotic complications. In addition, the patients were
maintained on paralytics and narcotics during ECMO support
to reduce stress and the oxygen demands. Under ECMO
support, the mechanical ventilator setting was adjusted
according to the lung-protection ventilator strategy (lowest
FiO2 to maintain SpO2  90%, ventilator rate 6e10/min,
pressure control mode with peak inspiratory pressure 
35 cm H2O, and positive end-expiratory pressure maintained
at 15 cmH2O) used to prevent ventilator-induced lung injury,
the complications of oxygen toxicity, and to maximize the
recruitment of functional residual lung capacity. Continuous
online circuit monitors were able to display the hematocrit,
pre- and postoxygenated blood oxygen saturation level
(BioTrend; Medtronic Inc., Anaheim, CA), blood flow rate,
and the prepump, preoxygenated, and postoxygenated
pressure. After adequate improvement of the patient’s
clinical hemodynamic status was achieved, attempts were
made to wean the patient off the ECMO system.
2.4. Statistical analysis
The demographic and clinical characteristics of the
patients are presented as the means standard deviations
(SD) or as proportions. The Mann-Whitney U test was used
to assess the impact of blood loss, blood transfusion, white
blood cell count, platelet count, prothrombin time, partial
thromboplastin time, C-reactive protein level, age, mean
tidal volume, and PaO2/FiO2 ratio between the surviving
and deceased patients. Noncontinuous data, including
chest X-ray findings, sex, and comorbidities such as
bacteremia, septic shock, bleeding tendency, diabetic
mellitus, and immunocompromised status were evaluated
using the Fisher exact test. The primary clinical outcome
was survival and discharge from the hospital. All statistical
analyses were performed using Stata 8.0 software (SAS
Corporation, College Station, TX, USA). Statistical signifi-
cance was defined as a p< 0.05.3. Results
Among our 14 patients (12 male, 2 female; median age: 39
years; range: 16e82 years), the indications for ECMO
support was status asthmaticus in one patient, adult
respiratory distress syndrome (ARDS) in nine patients, lung
transplantation with primary graft dysfunction in two
patients, acute myocardial infarction in one patient, and
unstable hemodynamics after the repair of a cardiac
penetration injury in one patient (Table 1). Hemothorax in
each patient in this study was unilateral (right side, 4; left
side, 9). Among the lung transplant and cardiac trauma
patients, hemothorax was not contributed to the previous
surgery during the subsequent operation for blood clot
evacuation. Nine of the 14 patients (64%) survived to
hospital discharge; one death was attributed to refractory
bleeding and four deaths were attributed to multiple organ
failure. Among these 14 patients, the mean ECMO circuit
duration was 570 436 hours (range: 45e1242 hours). Five
patients, including three survivors, received unusually long
periods of ECMO support (> 900 hours) due to severe ARDS
and pneumothorax with prolonged air leak. The median
interval between the start of ECMO and onset of pleural
hemorrhage was 12 days (range: 2e42 days).
The mean daily amount of blood transfusion during the
most active bleeding episode was 3431 2623.1 mL/day.
Blood transfusion (Mann-Whitney U test, pZ 0.039) and the
presence of a comorbidity (Fisher’s exact test, pZ 0.031)
were independent predictors of death (Table 2). However,
24-hour blood loss during the most active bleeding episode
did not significantly influence the clinical outcome
(pZ 0.423; Table 2). With coagulopathic correction,
control of bleeding was obtained in two patients after
decompression of the pleural cavity. In addition, another
four patients developed hemostasis without surgery after
pleural epinephrine irrigation through the chest tube.
Pleural epinephrine irrigation caused a mild increase in the
systolic blood pressure of these patients. Eight patients
required surgical intervention: two received VATS and six
received VATS that was then converted to open-window
thoracostomy for the management of hemithorax. More-
over, there were no specific findings (except blood clot
accumulation) that presented in every patient during
thoracotomy or VATS. Among our patients, three had to
delay their operations until the early discontinuation of
ECMO within 1 week. Three patients required repeated
operations for persistent bleeding. After surgical interven-
tion, oxygen saturation was temporarily increased in all
patients.
Furthermore, the mean tidal volume and PaO2/FiO2 ratio
during the most active bleeding episode tended to be lower
in nonsurvivors (pZ 0.096 and 0.841, respectively).
However, factors such as age (pZ 0.947), ECMO circuit
duration (pZ 0.317), and complicated pneumothorax
(pZ 0.301) did not statistically or significantly correlate
with mortality.
4. Discussion
ECMO is a common technique used to sustain life during
recovery from acute cardiopulmonary failure. Typically,
Table 1 The characteristics of massive hemothorax complicating ECMO in 14 patients and their clinical parameters during the most active bleeding episode.
Case No. Age/
Sex
Diagnosis Status while
ECMO setup
Mode of
ECMO support
Sites of
cannulation
(out/in)
Bleeding
amount
(ml/day)
Blood transfusion
(ml/day) (component)*
Management
modalities
Outcome
1 30/M Status asthmaticus 90 ml tidal volume VV RFV/ RIJV 580 280 (R280) Tube
thoracostomy
S
2 50/M Liver abscess with
ARDS, ARF
100% O2 demand VV RFV/ RIJV 1200 1060 (R440; W620) VATS, OW
thoracostomy
S
3 52/F Pulmonary
lymphangiomyomatosis
s/p LTx with ARDS, liver
failure
s/p LTx with
lung injury
VA RFV/ RFA 3390 4600 (R2315; F1280;
P1005)
VATS Mo
4 20/M Pneumonia with
septic shock, ARDS, ARF
100% O2 demand VA then VV LFV/ LFA 2210 1845 (R1260; F585) Tube
thoracostomy
S
5 38/M VSD with Eisenmenger
change s/p VSD repair
and ASD fenestration,
pneumonia, ARDS
ARDS with 100% O2
demand
VV LFV/ RIJV 2480 4755 (R2955; F1650;
P150)
VATS S
6 22/M Type I DM, empyema
with sepsis, ARDS
90% O2 demand VA->VA+VV->VV LFV/ LFA 1360 2750 (R1430; F710; P500;
C110)
VATS, OW
thoracostomy
Mo
7 54/M Acute myocardial
infarction with ARDS,
ARF
IABP used VV then VA LFV/ LFA 1350 7130 (R2915; F120;
P1410; W2685)
VATS, OW
thoracostomy
Mo
8 36/M Heart penetrating
injury, necrotizing
pneumonia with MOF
Cardiac
tamponade
with CPR
VV and VA RA/ Aorta 1080 10020 (R7120; C2900) VATS, OW
thoracostomy
Mo
9 16/M Septic arthritis,
pneumonia with MOF
CPR VA then VV LFV/ LFA 1350 4210 (R3680; P530) VATS, OW
thoracostomy
S
10 28/M ALL s/p BMT, CMV
pneumonitis with ARDS
100% O2 demand VV RFV/ RIJV 4080 2620 (R2000; P500; C120) VATS, OW
thoracostomy
Mo
11 30/F Paraneoplastic
pemphigus and
bronchiolitis obliterans
s/p LTx
s/p LTx with
lung injury
VA then VV LFV/ LFA 1670 3485 (R1300; F1420;
P765)
PEI S
12 56/M Pneumonia with septic
shock, ARDS, ARF
IABP used VV RFV/ RIJV 700 1240 (R360; P880) PEI S
13 34/M Pneumonia with ARDS 100% O2 demand VV RFV/ RIJV 900 1450 (R700; F750) PEI S
14 82/M Pneumonia with septic
shock, ARDS, ARF
100% O2 demand VV LFV/ RIJV 600 2590 (R1750; F330; P450;
C60)
PEI S
ALL: Acute lymphoblastic leukemia; ARDS: acute respiratory distress syndrome; ARF: acute renal failure; ASD: atrial septal defect; BMT: bone marrow transplantation; CMV: Cytomeg-
alovirus; DM: diabetic mellitus; F: female; LFA: left femoral artery; LFV: left femoral vein; LTx: lung transplantation; M: male; Mo: mortality; MOF: Multiple organ failure; OW: open
window; PEI: Pleural epinephrine irrigation; RA: right atrium; RFA: right femoral artery; RFV: right femoral vein; RIJV: right internal jugular vein; S: survival; s/p: status post;
VA: venoarterial; VATS: video-assisted thoracoscopic surgery; VSD: ventricular septal defect; VV: venovenous.
*: component: C: cryoprecipitate; F: fresh frozen plasma; P: platelet; R: packed red blood cell; W: whole blood.
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Table 2 Comparisons of the demographics, ECMO duration, and clinical characteristics during the most active bleeding
episode between the surviving and deceased patients.
Variable Surviving patients
(nZ 9) Mean SD
Deceased patients
(nZ 5) Mean SD
p
Age (y) 39.6 20.4 39.1 17.9 0.947
Male/female 8/1 4/1 1.0
Comorbidity 1/9 5/5 0.031
Duration of ECMO (h) 632.7 434.9 456.2 464.3 0.317
PaO2/FiO2 ratio 191.7 123.6 178.9 73.4 0.841
Tidal volume before treatmenta (mL) 516.0 123.7 484.0 91.3 0.853
Tidal volume (mL) during hemothorax 364.6 214.0 178.6 160.0 0.096
Tidal volume after treatment (mL) 524.6 106.6 527.3 89.9 0.540
Blood loss (mL/d) 1743.3 1251.5 2252.0 1380.2 0.423
Blood transfusion (mL/d) 2323.9 1534.2 5424.0 3151.4 0.039
Complicated pneumothorax 2/9 4/5 0.301
SD: standard deviation.
a Treatment included drainage, thoracoscopic surgery, or thoracotomy.
20 P.-M. Huang et al.anticoagulation is used from the initiation of the ECMO
circuit through the cessation of ECMO support. Hemorrhage
is an important complication of ECMO with a reported
incidence of 12.2%.5 Hemothorax is associated with an
80e100% risk of mortality when conventionally treated,8
such as by adjusting the heparin dosage or the drainage
of pleural hemorrhage.9 Some of these complications are
related to the primary disease and some are related to
systemic anticoagulation. In addition, a pre-ECMO history of
chest needle aspiration is also important because compli-
cations such as hemothorax or hemopericardium can arise
once ECMO is initiated,9 as occurred in one of our patients.
Chest radiography remains the mainstay of the diagnosis ofFigure 2 Management algorithm for ECMO-related massive hemot
blood loss.hemithorax,10 but computed tomography and sonography
provide better imaging of the surrounding structures when
considering surgical intervention.
Because ECMO patients are critically ill and frequently
have coexisting conditions, half of our patients were diag-
nosed with multiple organ failure. Without a doubt, it is
very difficult to identify the factors associated with survival
in this small cohort of patients with diverse diagnoses.
However, blood transfusion and comorbidity were deter-
mined to be factors related to survival outcome in this
study. Increased blood transfusion demand results in the
greater deterioration of the patient’s physiological condi-
tion. When confronting this troublesome situation,horax based on indications, hemodynamics, and the quantity of
Table 3 Outcomes of ECMO-related massive hemothorax.
Hemothorax no. Surviving Treatment
Wagner 199020 2 1 Thoracotomy
Nagaraj 19929,a 6 0 5 tube thoracostomy;1 thoracotomy
Lidegran 200512 4 2 1 conservative; 3 thoracotomy
Marasco 20076 4 1 Adjust anticoagulant dosage
Huang et al. 14 9 Multimodality strategy
a This study examined neonates.
Massive hemothorax and ECMO 21adjusting the heparin dosage is the only treatment
mentioned in the literature,6, 11 and the results are
discouraging. Based on our experiences of treating patients
with hemothorax-complicated ECMO, we propose a thera-
peutic algorithm for the treatment of these critically ill
patients (Fig. 2). Treatment of the underlying disease and
adjusting the anticoagulant therapy are mandatory when
hemothorax occurs. Major surgical intervention must be
postponed, if possible, until near the termination of ECMO
therapy or until the patient can be rapidly weaned off
ECMO because bleeding tendency contributes to post-
operatively persistent hemothorax.12 Furthermore, these
patients are often so critically ill that they might be
unsuitable for surgery. Although our experiences suggest
that surgical intervention while on ECMO is technically
feasible, three of our patients postponed hemothorax
evacuation until the ECMO circuit was discontinued.
Drainage of these hemorrhage results in the improvement
of the patient’s clinical status and is possibly essential to
the patient’s survival. Drainage of hemothorax allows for
the apposition of the visceral and parietal pleura, which
aids hemostasis.13 Clamping of the chest tube does not
decrease hemorrhage or hypotension, but it does nega-
tively affect gas exchange, decrease PaO2, and is associ-
ated with significant hypercapnia. Therefore, chest tube
clamping is not recommended for the treatment of massive
hemothorax.13 Recombinant activated factor VII (rFVIIa) is
a drug with proven efficacy for counteracting intractable
hemorrhage in various scenarios. Its use in patients on
ECMO, however, is limited by the increased risk of throm-
botic events.14,15 Moreover, neither a reduction in chest
tube output nor blood transfusion requirements reached
a level of statistical significance when using rFVIIa to treat
ECMO-related hemothorax.16
Massive hemothorax and continual bleeding with
unstable hemodynamics are indications for further surgical
intervention,17 especially if conventional treatment has
failed. VATS plays an important role in the diagnosis and
treatment of certain thoracic injuries.18 For the treatment
of retained hemothorax, VATS is the favored alternative to
thoracotomy for evacuation and adequate hemothorax
drainage. However, to avoid prolonged surgery and to
control intractable hemothorax, conversion to open-
window thoracostomy due to soaked dressings is another
alternative method for treating critically ill patients. We
also developed the use of pleural epinephrine irrigation,
which stimulates vascular contractions and further
improves hemostasis. Before definitive surgical treatment
for hemothorax, we recommend that pleural lavaged
streams of epinephrine be used first. However, somehemothoraces (e.g., in patients with ruptured great
vessels, organ rupture, or massive postoperative hemo-
thorax) require indispensably immediate and definitive
surgical intervention. Therefore, pleural epinephrine irri-
gation should not be continuously used if bleeding does not
stop or decrease.
Though the case number is limited and the survival rate
(64%) needs to be improved in this study, it is the largest
series available on this serious complication (Table 3).
Based on our experiences and the findings of previous
reports,6,11,19e21 we recommend an algorithm-guided
approach to effectively determine whether surgical explo-
ration is necessary or whether nonoperative treatment is
sufficient for ECMO patients with massive hemothorax. In
conclusion, ECMO-related massive hemothorax usually
occurs unilaterally and presents as a life-threatening
condition. With intensive treatment, nearly two-thirds of
the patients were saved. The significant risk factor for
mortality was the presence of a comorbidity such as sepsis,
diabetic mellitus, or immunocompromised status. Further
research is required to optimize patient selection, deter-
mine the optimal treatment strategies, and establish the
important predictors of clinical outcome.Acknowledgments
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